Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.

Abstract

In this sample, the majority of patients with RA were treated with a single TNF-α antagonist over the first year on therapy.

For those who switched therapy, Year 2 RA-related and total direct healthcare costs were higher, adjusting for claims-based measures of RA disease severity.

Full Text

• DOI - The Journal of rheumatology (DOI)
• Swets Information Services - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Antirheumatic Agents
• Arthritis, Rheumatoid
• Cost of Illness
• Female
• Health Care Costs
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Tumor Necrosis Factor-alpha

Similar articles

• Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. (2003-05-21)
• Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. (2012-11-01)
• Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. (2007-08-09)
• Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). (2006-02-20)
• Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. (2013-03-12)
• Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. (2006-12-13)
• Determinants of direct costs in Dutch rheumatoid arthritis patients. (2004-06-14)
• Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. (2012-11-15)
• A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. (2013-04-12)

Authors

• Stephan McBride
• Khaled Sarsour
• Leigh Ann White
• David R Nelson
• Anita J Chawla
• Joseph A Johnston

Publication date

2011-10-03

Journal

Journal topics

• Arthritis
• Rheumatic Diseases

Language

Eng.

Copyright

The Journal of rheumatology

Analysis Group Inc., 1010 El Camino Real, Suite 310, Menlo Park, CA 94025, USA. smcbride [at] analysisgroup.com

Release reference

J Rheumatol. 2011 Oct;38(10):2141-9

Related books

• Books of Antirheumatic Agents
• Books of Arthritis
• Books of Arthritis, Rheumatoid
• Books of Cost of Illness
• Books of Health Care Costs
• Books of Retrospective Studies
• Books of Rheumatic Diseases
• Books of Tumor Necrosis Factor-alpha